Physician profile
Jason King
NPI 1255710117
$4,065.32
in general payments reported to CMS, 2019-2025
38 companies · $703 in 2025
The $703 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $85.48 · 2021: $1,255 · 2022: $721 · 2023: $825 · 2024: $476 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,968 · Education: $35.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,967.98 |
| Education | $35.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,030.48 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $236.14 | 2021-2024 | Rytary, Ongentys |
| Biogen, INC. | $204.94 | 2020-2025 | Tysabri, Vumerity |
| Teva Pharmaceuticals USA, INC. | $204.25 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Alexion Pharmaceuticals, INC. | $196.29 | 2022-2025 | Ultomiris |
| Sk Life Science, INC. | $193.72 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $183.55 | 2021-2024 | |
| Lundbeck LLC | $158.88 | 2022-2025 | Vyepti, Rexulti |
| Csl Behring | $147.09 | 2022-2023 | Hizentra |
| Livanova USA, INC. | $139.83 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Tg Therapeutics, INC. | $125.84 | 2024-2025 | |
| Celgene Corporation | $119.18 | 2023-2025 | Zeposia |
| Abbvie INC. | $119.06 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $106.09 | 2022-2025 | Ongentys, Ingrezza |
| Argenx US, INC. | $75.08 | 2024-2025 | Vyvgart Hytrulo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $74.78 | 2022-2025 | Nuplazid |
| Corium, LLC | $73.40 | 2022-2023 | Adlarity |
| Amgen INC. | $70.16 | 2021 | |
| Genentech USA, INC. | $57.50 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Janssen Pharmaceuticals, INC | $56.46 | 2022 | |
| Alkermes, INC. | $56.14 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $48.03 | 2022-2023 | Rexulti, Abilify Maintena |
| Allergan, INC. | $44.69 | 2020 | |
| Pfizer INC. | $42.64 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $36.61 | 2023 | Aptiom |
| Avion Pharmaceuticals | $35.08 | 2022 | |
| Kyowa Kirin, INC. | $33.85 | 2023 | Nourianz |
| Eisai INC. | $30.49 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $23.18 | 2023 | |
| Genzyme Corporation | $21.43 | 2022 | |
| Dentsply Sirona INC | $20.00 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.16 | 2023 | |
| Almatica Pharma LLC | $17.91 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.59 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.79 | 2021 | |
| Impel Pharmaceuticals INC. | $14.85 | 2023 | Trudhesa |
| Alfasigma USA, INC. | $13.07 | 2021 | |
| Ge Healthcare | $2.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.